ASX Health Quarterly Wrap: Control Bionics makes 15pc sales revenue jump
The June results are particularly pertinent as the last quarter of the financial year in Australia, providing an overview of the full year for many companies.
Control Bionics (ASX:CBL)
Control Bionics delivered a record year, with unaudited sales revenue rising 15% to more than $6 million and total revenue exceeding $7m in FY25. The company also reported an 8% lift in cash receipts, reaching $5.7m.
During the quarter Control Bionics officially launched its NeuroNode Only sales model in the US following issuance of US Medicare reimbursement code E2513 under the Healthcare Common Procedure Coding System (HCPCS), locking in a rate of US$4300 (A$6600) per device.
NeuroNode is a wearable, watch-like, wireless non-invasive electromyography (EMG) or spatial sensor device to assist people with physical disabilities perform everyday functions. Notably, this includes sufferers of cerebral palsy or motor neurone disease.
Control Bionics said the US HCPCS reimbursement code laid the foundation for continued growth in the US, its largest addressable market. Discussions with multiple potential distribution partners in the US are well advanced.
Control Bionics' Neuro Elite Athletics program NeuroBounce continues to gain commercial traction, diversifying its EMG technology into the sports performance market.
Control Bionics has launched NeuroBounce in Australia with all five athletes in the initial four-week program improving their vertical jump height, with one recording an increase of 14 centimetres.
Meanwhile, the company's NeuroNode device continues to gain traction in global markets. Following adoption within the UK's National Health Service (NHS), Control Bionics is now in active partnership discussions in both Europe and the US as it builds out its distribution-only strategy.
In its NeuroStrip product line, Control Bionics has begun collecting EMG-labelled data from athletes and rehabilitation facilities with its development team now assessing opportunities to incorporate AI solutions to automate elements of the system.
NeuroStrip hardware is now in use in both Australia and the US, with clinical evaluations underway across several areas.
With growing international interest, expanding product lines, and a clear focus on commercialisation, Control Bionics said it had entered FY26 with strong momentum and multiple catalysts for further growth.
Alterity Therapeutics (ASX:ATH)
CEO and managing director Dr David Stamler said US Food and Drug Administration (FDA) fast track designation for ATH434 in multiple system atrophy (MSA) was the highlight of the recent quarter that also featured additional positive clinical data from its Phase 2 double-blind trial.
"Receiving fast track designation alongside the orphan drug designation we have already received underscores the promise of this potentially disease-modifying therapy to address the urgent needs of individuals with MSA," he said.
"In addition, we presented additional efficacy data from the ATH434-201 double-blind trial at prominent medical meetings, including slowing of disease progression on the Unified MSA Rating Scale or UMSARS, improvement in key symptoms of MSA, and preserved activity in the outpatient setting."
Following quarter end Alterity this week announced positive results from its ATH434-202 open-label phase II clinical trial, in which ATH434 demonstrated a clinical benefit on the UMSARS and global assessments of neurological symptoms.
Neuroimaging biomarkers showed target engagement and slowed brain atrophy in a manner consistent with the double-blind study findings with ATH434 continuing to demonstrate a favourable safety profile.
"These data reinforce our confidence in the MSA program as we prepare for interactions with the US FDA," Stamler said.
Alterity's cash position on June 30 was $40.66m, with operating cash outflows for the quarter of $2.35m.
Neurotech International (ASX:NTI)
Positive human PK study results for NTI164 released in June following preclinical toxicology results in May
Data from Rett Syndrome program presented at the International Rett syndrome Foundation (IRSF) Annual Scientific Meeting
Neurotech initiated formal engagement with US FDA in preparation for lodging an investigational new drug (IND) application in FY26
Neurotech's June quarter was marked by important clinical progress, growing international recognition, and further regulatory engagement for its lead investigational therapy NTI164, a proprietary CBDA-rich cannabinoid formulation being developed for paediatric neurological and inflammatory brain disorders.
The company completed its first-in-human pharmacokinetic (PK) study. Conducted in healthy adult volunteers, the study confirmed that NTI164 is rapidly and predictably absorbed, with CBDA reaching peak plasma levels within 2–4 hours and emerging as the dominant circulating cannabinoid.
Neurotech said the results validated NTI164's systemic stability, safety, and potential suitability for paediatric use.
The PK study builds on preclinical toxicology results released in May, which demonstrated excellent tolerability in rats and dogs under GLP conditions.
Neurotech also presented data from its Rett syndrome program at the International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting in Boston.
Following the quarter, Neurotech announced that results from its phase I/II open-label clinical trial in Rett syndrome had been published in the Journal of Paediatrics and Child Health, a peer-reviewed scientific journal.
Neurotech continued to progress its dual regulatory pathway strategy in Australia and the US during the quarter. In Australia, the company is moving toward potential product registration with the therapeutic Goods Administration (TGA) and is exploring expedited approval options to support timely market entry.
The company has initiated formal engagement with the FDA in preparation for lodging an investigational new drug (IND) application in FY26.
In June, Neurotech appointed leading US clinician Dr Bonni Goldstein as chief medical advisor USA, who has more than 25 years of clinical experience, including 17 years specialising in cannabinoid-based medicine.
Goldstein is internationally recognised as a pioneer in paediatric cannabinoid therapy and brings key expertise as NTI164 progresses its development pathway.
Also in June, CEO Dr Anthony Filippis attended the BIO International Convention in Boston as Neurotech continues to elevate its global profile and explore partnering and funding opportunities.
Neurotech placed its wholly owned subsidiaries AAT Medical Ltd and AAT Research Ltd, responsible for the Mente neurofeedback device, into voluntary liquidation. The move reflects the company's focus on advancing NTI164.
Operating cash outflows for the quarter were $2.6m, primarily driven by R&D expenditure supporting its FDA IND and TGA submissions, as well as clinical trial extension costs.
Neurotech ended the period with $3m in cash and expects reduced outflows in Q1 FY26. A ~$3m R&D tax refund is anticipated in Q1 or early Q2 FY26 to further bolster cash reserves.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News AU
2 minutes ago
- Sky News AU
Mike Pezzullo warns AUKUS will demand an ‘all-consuming' national effort and raises questions over Australia's readiness
Former Home Affairs Secretary Mike Pezzullo has issued a blunt warning about the scale and urgency of Australia's AUKUS commitments, saying the nuclear submarine programme will demand a national effort on par with Medicare. Speaking to Sky News Australia following revelations that the Department of Defence has extended its timeline for a key AUKUS review, Mr Pezzullo said the initiative must become a whole-of-society undertaking as he raises concerns about whether Australia, and its US partner, can deliver. 'In military terms, AUKUS is as big a programme relative to our military capability as Medicare is to health,' he said. 'It's like having the military version of Medicare. It's something that's got to become an all-consuming, focused effort that transcends Commonwealth, state, territory governments into industry, academia, the training pipeline through both universities and vocational educational training institutions.' The extended review is now expected to include wider consultations with the UK Government, US Congress, and other stakeholders, including industry. Pezzullo said the review would likely centre on three key concerns: Australia's readiness, US industrial capacity, and the long-term strategic implications of Australia acquiring eight nuclear-powered submarines. 'The Americans will want to assess that because if we're not ready, then they'll put an X against that or a question mark at least,' he said. He pointed to recent comments by Admiral Caudle, the incoming head of the US Navy, who told the Senate Armed Services Committee that America's submarine output must double to meet both domestic and allied needs. 'He said a 10 or 20 per cent lift in productivity will not cut it. We have to double the productivity,' Pezzullo said. 'If he's saying that, we should be concerned because it then becomes a question mark as to whether there's any available for us.' Even if production and training targets are met, Pezzullo believes the US still harbours concerns about the strategic direction of the partnership. 'The fundamental concern I think Americans really have is, are we putting all this investment in to create an autonomous, independent Australian capability that we'll never be able to jointly use, or are they willing to talk to us about that joint use?' Turning to Australia's short-term naval posture, Pezzullo flagged a critical capability gap between 2025 and 2032, when the first Virginia-class submarine is expected to arrive, arguing the government must act urgently to extend the life of the existing Collins-class fleet. 'If we can't extend Collins to get us through that seven-year gap, we've got a real problem,' he said. While some have suggested a leasing arrangement or interim acquisition, Pezzullo said a more radical solution could also be on the table. 'The more radical innovative approach is to go full Ukrainian and go for a very large fleet of uncrewed long-range, medium-range and short-range vessels to undertake missions,' he said. 'They're not as capable as a submarine but if you have lots of them, you might be able to fill the gap.'
SBS Australia
2 minutes ago
- SBS Australia
Australia avoids latest round of US tariffs
Australia avoids latest round of US tariffs Uluru Dialogue condemns lack of progress on Closing the Gap targets Australia wins women's 200 metre freestyle final at World Championships Australia has avoided a fresh wave of tariffs, after the Trump administration announced new import taxes targeting dozens of other countries. The White House confirmed that President Trump would raise tariffs on products from nations that, in his words, failed to engage in negotiations with the United States or to align on economic and national security matters. Australia has been spared, with its goods to remain under a baseline 10 per cent tariff. By contrast, New Zealand imports will face a 15 per cent rate, while Canada and others have been hit with even harsher penalties. The decision comes amid ongoing U-S concerns over non-tariff trade barriers, including Australia's biosecurity rules. Canberra recently eased restrictions on American beef, but ministers insist the timing was unrelated to the tariff announcement. The Uluru Dialogue has issued a strong statement ahead of the Garma Festival, declaring 'enough is enough' on Closing the Gap. It says progress has stalled, and in some areas, is going backwards. It blames government inaction, outdated bureaucracy, and the ongoing exclusion of Indigenous voices. In a statement, the Uluru Dialogue says without a Voice to Parliament, decisions are still being made without Indigenous input. "We continue to be sold the status quo as the solution, but how can we see any progress on Closing the Gap by doing more of the same? Our children are being locked up, our Elders are dying, and our people are continuing to live in a country where their rights are neglected. Their voices and calls for help falling on deaf ears." Closing the Gap is a national plan to improve health, education, and life expectancy for First Nations people, but only four of 19 targets are on track. The government is expected to highlight progress on 10 of 15 measures at Garma, but the group says that won't resonate with struggling communities. The Garma Festival runs from today to the 4th of August in northeast Arnhem Land, on Yolngu country. An underworld war looms in Melbourne after the daylight execution of 26-year-old Athan Boursinos, who had known links to organised crime. The son of a former police officer, he was gunned down around 9:30am yesterday outside his home in Wollert as he was heading to court, a tactic often used by gangs to ambush rivals. Eight shots were heard by neighbours. Detective Inspector Dean Thomas is with the Victoria Police. "This is deliberate and obviously targeted. We will work now to piece together what has gone on." Athan Boursinos had been a person of interest in the killing of underworld figure Sam Abdul Rahim, and his death has sparked concerns of violent retaliation linked to the ongoing illicit tobacco wars. Police says investigators are now working to prevent further bloodshed. Russian missile and drone attacks have killed at least 15 people and injured 155 others in Kyiv, as Russia's President defies United States President Donald Trump's ceasefire deadline. Rescue crews were seen sifting through the debris following attacks on 27 locations across four Kyiv districts Thursday night. Senior US diplomat John Kelley tells the 15-member United Nations Security Council that President Trump wants a deal to end Russia's war in Ukraine within one week. "Both Russia and Ukraine must negotiate a ceasefire and durable peace. It is time to make a deal. President Trump has made clear this must be done by August 8. The United States is prepared to implement additional measures to secure peace." Two Australians arrested by Israeli forces aboard the Freedom Flotilla boat Handala have returned safely to Australia. Tan Safi and Robert Martin were among 19 activists trying to breach Israel's blockade of Gaza to deliver aid including nappies and baby formula. The boat was intercepted in international waters on the 26th of July by Israeli soldiers and towed to Ashdod. This morning, supporters greeted them at the airport waving Palestinian flags and chanting as they reunited with loved ones. Ms Safi describes the treatment they faced in Israeli custody, especially that of fellow activist Chris Smalls, co-founder of the Amazon Labor Union. "They pinned him down on the floor, seven or eight of them, and when i asked about him, they came into the room and dragged me out by my arms. I'm still bruised here on my arms from it. They pulled me out and threw me down on the floor, and they made me take off all my clothes. They strip searched me right there, made me, squat, up and down, and then go through all my things. And after that, maybe an hour passed, and we were able to see someone from the Australian Embassy." The Handala was part of a wider Freedom Flotilla effort to raise awareness about conditions in Gaza. All foreign nationals have since been deported from Israel. To sport and in swimming, Australia has won the women's four by 200 metre freestyle relay final at the World Championships in Singapore. The victory, securing Mollie O'Callaghan 11 world titles - equal to the record set by legend of the pool, fellow Australian Ian Thorpe. Kyle Chalmers placed third 100 metres freestyle final at the event overnight. The Australian came close to breaking the 46-second barrier in the race but fell just short of the mark. Chalmers tells Channel 9 he is content with the result as he focuses on the arrival of his child. "I have been training hard for that moment. I desperately wanted to get a 46 out tonight but wasn't quite there. But to get on a podium is so special. I'm just really excited to go home now and become a dad and that is my biggest priority this year. That was just a bit of fun and I enjoyed being part of that race."
News.com.au
2 minutes ago
- News.com.au
Field of dreams: Racing Victoria has time to unlock Oaklands potential
Racing Victoria has a luxury of time and potential to make right decisions on its multimillion dollar Oaklands Park dream field. A changed Melbourne racing infrastructure landscape, since RV paid $25.3m in late 2022 for the green wedge-zoned land, has afforded the regulator options. The 400-hectare site, close to Melbourne Airport, was bought to potentially build an equine super-centre, including racecourse and training complex. The future of Sandown Racecourse was uncertain at the time, while a second track at Caulfield was yet to be developed. The Valley redevelopment is also set to start this year. The green field, bound by Oaklands, Craigieburn and Mickleham roads, is three times the size of Flemington Racecourse precinct and six-times Rosehill Gardens in Sydney. Residential estates and developments have crept closer to RV's prized parcel of land, which is also inside a proposed State Government outer ring road project. RV chief executive Aaron Morrison has sought internal and external expert advice on the North-West Land 'looking for the best option'. 'What is the best and greatest use of that site?' Morrison said. 'Unless there is a very specific reason why that patch of grass would make the best training facility, it may be we're better off holding and looking at our other options.' Morrison confirmed a new racecourse development at Oaklands was 'unlikely'. 'We're constantly looking at what's the right footprint,' Morrison said. 'Operating footprint from a racing perspective, a training perspective … we now look at it and go 'we don't need another racetrack really?' 'It's unlikely we're going to develop anything for racing … perhaps we may need it for training. 'The most obvious consideration is training and opportunity to build a whole equine ecosystem around it (vet centre, equine industry education). 'Right now, we don't have an absolute pressing need for it.' Major centres Southside (Cranbourne and Pakenham), Flemington, Ballarat and Mornington currently host the majority of Melbourne racing stables. Flemington, the only training centre left in the heart of Melbourne following the closure of the Caulfield complex, has lease agreements in place to 2030. 'We're accommodating training across the state pretty well and we're starting to really look at (Oaklands) and say, well, is it the best use of industry funds to spend $100m-$120m developing a greenfield site?' Morrison said. 'Do we need it (new training centre) at the moment? Not, not at the moment. 'While Flemington retains training on their site, we don't have a burning need to go and redevelop (Oaklands) just yet.' • Brad Waters' best bets, race-by-race analysis for Flemington on Saturday Morrison said investment in existing training centres could be more beneficial to the industry. 'The good news is that asset has got a lot of value,' Morrison said. 'Certainly worth far more than when we bought it and with any reasonable rezoning it is worth quite a lot more. 'For now … might be its best value to the industry, sitting on an asset worth quite a lot of value. 'We bought it for $25m, right now, undeveloped, it'd be at least double that. 'Maybe more and then depending on rezoning, the potential is a lot more.' 'We were the common enemy' In September last year, @RacingVictoria CEO Aaron Morrison walked into a furnace of agitated stakeholders in the boardroom at Epsom Rd. Today, he reveals to @gilbertgardiner how the industry got back on track. ðŸ'‡ — Racenet (@RacenetTweets) July 30, 2025 A future fund nest egg of about $65m and valuable media assets underpin 'the strength of the Victorian industry'. 'We're not here to make profit for profit's sake,' Morrison said. 'Everything we do is to be reinvested back into supporting, sustaining and growing the racing industry and all the participants involved in it.' 'It's great to have a permanent horse presence in the CBD,' Morrison said.
